In recent years, the demand for DNA in the form of plasmid DNA has gone up dramatically. The demand has significantly risen in the last couple of years because of large-scale gene and cell therapies and the outbreak of Covid-19 and subsequent vaccines. The state-of-art therapies and treatment measures are transforming the healthcare industry in fighting deadly diseases. Thanks to pre-clinical plasmid manufacturing in different forms or modes.
Elevated demand for plasmids
A few years back, plasmid DNA was mainly used in a laboratory or academia. The vital role of plasmid DNA in the pharma industry began with the production of therapeutic proteins. The prominent players in the pharma and healthcare sectors support the manufacturing of plasmid DNA on a large scale. The demand for high-quantity and top-notch quality plasmids has risen in a couple of years. Rapid growth in the cell and gene therapy industry has a significant role to play in elevated plasmid manufacturing scale.
Inclination towards a commercial arena
Tons of biopharmaceutical enterprises are using plasmid DNA for clinical experiments and developments. Furthermore, it is also used within a wide array of products that have the license for commercial distribution. The FDA has also accounted for an increase in the early development of cell and gene therapy products and IND or investigational new drug operations. It is anticipated that by 2025 the international cell and gene therapy market will be valued at more than $15 billion. There has been a rapid shift in the industry toward the commercial domain. Henceforth, there has been an urgency in the rising demand for high-quality and high-scale pre-clinical plasmid manufacturing and production.
Why is plasmid DNA so high in demand?
Top-notch quality plasmid DNA is the prime component in the manufacturing of cell and gene therapy medicines, vaccines, and other products. Henceforth, it is in high demand. This has resulted in the need to optimize the process of manufacturing therapeutics so that the demand for volume and high quality can be catered to. Plasmid DNA manufacturing has to encounter multiple challenges because of high viscosity, large size, and impurities during the process. Hence, it is expected to have a basic understanding of the entire process as it is critical in large-scale manufacturing.
Shortage of plasmids
There is a shortage of high-quality plasmid DNA because of the significant growth of the international gene and cell therapy landscape. Additionally, the cancer treatment application and products along with vaccines have also surged. The number of IND products and large-scale commercial distribution of multiple drugs and application that requires plasmids has led to the short supply. The Covid-19 pandemic has aggravated the shortage because of the experimentation with DNA-based vaccines.
Plasmid DNA plays a key role in the development and manufacturing of critical drugs. The pre-clinical plasmid manufacturing has a significant function in producing next-generation gene and cell vaccines and therapies. The big names of the pharma and healthcare industry are investing huge capital in the manufacturing of DNA-based vaccines, medicines, and therapeutics.